mRNA |
ML210 |
CTRPv2 |
pan-cancer |
AAC |
-0.048 |
0.1 |
mRNA |
Rapamycin |
CTRPv2 |
pan-cancer |
AAC |
0.05 |
0.1 |
mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.053 |
0.1 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.049 |
0.1 |
mRNA |
ML239 |
CTRPv2 |
pan-cancer |
AAC |
-0.051 |
0.1 |
mRNA |
elocalcitol |
CTRPv2 |
pan-cancer |
AAC |
-0.049 |
0.1 |
mRNA |
BRD-K85133207 |
CTRPv2 |
pan-cancer |
AAC |
-0.053 |
0.1 |
mRNA |
Erlotinib |
UHNBreast |
pan-cancer |
AAC |
0.41 |
0.1 |
mRNA |
BRD-K42260513 |
CTRPv2 |
pan-cancer |
AAC |
0.079 |
0.1 |
mRNA |
tretinoin:carboplatin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.049 |
0.2 |